Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

16 Aug 2024

Abstract excerpt

Improvement of outcome in patients with pancreatic ductal adenocarcinoma (PDAC) requires exploration of novel therapeutic targets. Thus far, most studies of PDAC therapies, including those inhibiting small ubiquitin-like modifications (SUMOylation), have focused on PDAC epithelial cell biology, yet SUMOylation occurs in a variety of cell types. The mechanisms by which SUMOylation impacts PDAC in the context of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Immune cells in cancer
Share to Peptidase Inhibition and Analysis
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39150446
DOI: 10.1158/1535-7163.mct-23-0572

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor MicroenvironmentPMID 39150446Read ↗

The SUMO pathway in pancreatic cancer: insights and inhibitionSemantic proximity Read ↗

Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypesSemantic proximity Read ↗

Targeting tumor-intrinsic TAK1 triggers anti-tumor immunity and sensitizes pancreatic cancer to checkpoint blockadeSemantic proximity Read ↗

Plectin promotes an aggressive phenotype and represses cytotoxic T cell activity in pancreatic cancerSemantic proximity Read ↗

Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypesSemantic proximity Read ↗

Cross-species single-cell atlases chart progression, therapy-driven remodelling and immune evasion in pancreatic cancerSemantic proximity Read ↗

Distinct small molecule inhibitors of Kras specifically prime CTLA4 blockade therapy to transcriptionally reprogram Tregs and overcome resistance to suppress pancreas cancerSemantic proximity Read ↗

Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell TherapiesSemantic proximity Read ↗

Oncogenic Kras <sup>G12D</sup> specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8 <sup>+</sup> T cells dependent mannerSemantic proximity Read ↗

Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencingSemantic proximity Read ↗

Epigenetic and Transcriptional Control of the Epidermal Growth Factor Receptor Regulates the Tumor Immune Microenvironment in Pancreatic Cancer.Semantic proximity Read ↗

TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.